Meta-Analysishigh evidence
Rethinking diabetes as a modifier of the weight-loss response to incretin-based therapies. A twin trial meta-regression.
Nutrition, metabolism, and cardiovascular diseases : NMCD·July 1, 2026·PMID 41997798
Why it mattersClinicians often perceive that incretin therapies are less effective for weight loss in patients with diabetes. This analysis clarifies that the attenuated response is largely attributable to concomitant patient factors, not diabetes itself, which can guide realistic expectations and patient selection.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled